Lymphocytic infiltration and immune activation in metallothionein promoter-exendin-4 (MT-exendin) transgenic mice

Diabetes

Volumn 55, Issue 6, 2006, Pages 1562-1570

  Baggio, Laurie L ^a   Holland, Dianne ^a   Wither, Joan ^a   Drucker, Daniel J ^a,b  

^a UNIVERSITY OF TORONTO   (Canada)

^b TORONTO GENERAL HOSPITAL   (Canada)

Author keywords

ConA, concanavalin A; DPP 4, dipeptidyl peptidase 4; DsDNA, double stranded DNA; ELISA, enzyme linked immunosorbent assay; ENTP, exendin NH 2 terminal peptide; Ex 4, exendin 4; GLP 1, glucagon like peptide 1; GST, glutathione S transferase

Indexed keywords

ANTIBODY; EXENDIN 4;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CD4 CD8 RATIO; CELL ISOLATION; CELLULAR DISTRIBUTION; CONTROLLED STUDY; IMMUNITY; LYMPHOCYTE; LYMPHOCYTIC INFILTRATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; TRANSGENIC MOUSE;

ANIMALS; ANTIGENS, CD45; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CELL PROLIFERATION; CELLS, CULTURED; FEMALE; GLUCAGON-LIKE PEPTIDE 1; IMMUNIZATION; IMMUNOHISTOCHEMISTRY; KIDNEY; LIVER; LYMPHOCYTES; MACROPHAGES; MALE; METALLOTHIONEIN; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; PANCREAS; PEPTIDES; PROMOTER REGIONS (GENETICS); RECEPTORS, GLUCAGON; VENOMS;

EID: 33748319404     PISSN: 00121797     EISSN: 00121797     Source Type: Journal    
DOI: 10.2337/db05-1502     Document Type: Article

References (27)

1. Brubaker PL, Drucker DJ: Glucagon-like peptides regulate cell proliferation and apoptosis in the pancreas, gut, and central nervous system (Minireview). Endocrinology 145:2653-2659, 2004
2. Meier JJ, Gallwitz B, Schmidt WE, Nauck MA: Glucagon-like peptide 1 as a regulator of food intake and body weight: therapeutic perspectives. Eur J Pharmacol 440:269-279, 2002
3. Zander M, Madsbad S, Madsen JL, Holst JJ: Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and beta-cell function in type 2 diabetes: a parallel-group study. Lancet 359:824-830, 2002
4. 2-terminus in type II diabetic patients and in healthy subjects. Diabetes 44:1126-1131, 1995
5. Kolterman OG, Buse JB, Fineman MS, Gaines E, Heintz S, Bicsak TA, Taylor K, Kim D, Aisporna M, Wang Y, Baron AD: Synthetic exendin-4 (exenatide) significantly reduces postprandial and fasting plasma glucose in subjects with type 2 diabetes. J Clin Endocrinol Metab 88:3082-3089, 2003
6. Chang AM, Jakobsen G, Sturis J, Smith MJ, Bloem CJ, An B, Galecki A, Halter JB: The GLP-1 derivative NN2211 restores β-cell sensitivity to glucose in type 2 diabetic patients after a single dose. Diabetes 52:1786-1791, 2003
7. Buse JB, Henry RR, Han J, Kim DD, Fineman MS, Baron AD: Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes. Diabetes Care 27:2628-2635, 2004
8. DeFronzo RA, Ratner RE, Han J, Kim DD, Fineman MS, Baron AD: Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. Diabetes Care 28:1092-1100, 2005
9. Kendall DM, Riddle MC, Rosenstock J, Zhuang D, Kim DD, Fineman MS, Baron AD: Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea. Diabetes Care 28:1083-1091, 2005
10. Burcelin R, Rolland E, Dolci W, Germain S, Carrel V, Thorens B: Encapsulated, genetically engineered cells, secreting glucagon-like peptide-1 for the treatment of non-insulin-dependent diabetes mellitus. Ann N Y Acad Sci 875:277-285, 1999
11. Baggio L, Adatia F, Bock T, Brubaker PL, Drucker DJ: Sustained expression of exendin-4 does not perturb glucose homeostasis, beta-cell mass, or food intake in metallothionein-preproexendin transgenic mice. J Biol Chem 275:34471-34477, 2000
12. Adatia FA, Baggio LL, Xiao Q, Drucker DJ, Brubaker PL: Cellular specificity of proexendin-4 processing in mammalian cells in vitro and in vivo. Endocrinology 143:3464-3471, 2002
13. Baggio LL, Kim JG, Drucker DJ: Chronic exposure to GLP-1R agonists promotes homologous GLP-1 receptor desensitization in vitro but does not attenuate GLP-1R-dependent glucose homeostasis in vivo. Diabetes 53 (Suppl. 3):S205-S214, 2004
14. Chen YE, Drucker DJ: Tissue-specific expression of unique mRNAs that encode proglucagon-derived peptides or exendin 4 in the lizard. J Biol Chem 272:4108-4115, 1997
15. Levine S, Sowinski R: Experimental allergic encephalomyelitis in inbred and outbred mice. J Immunol 110:139-143, 1973
16. Yoshimoto T, Bendelac A, Hu-Li J, Paul WE: Defective IgE production by SJL mice is linked to the absence of CD4+, NK1.1+ T cells that promptly produce interleukin 4. Proc Natl Acad Sci U S A 92:11931-11934, 1995
17. Kung SK, Su RC, Shannon J, Miller RG: The NKR-P1B gene product is an inhibitory receptor on SJL/J NK cells. J Immunol 162:5876-5887, 1999
18. Murphy ED: SJL/J, a new inbred strain of mouse with a high, early incidence of reticulum-cell neoplasms. Proc Am Assoc Cancer Res 4:46, 1963
19. Weller AH, Magliato SA, Bell KP, Rosenberg NL: Spontaneous myopathy in the SJL/J mouse: pathology and strength loss. Muscle Nerve 20:72-82, 1977
20. Pohl M, Wank SA: Molecular cloning of the helodermin and exendin-4 cDNAs in the lizard: relationship to vasoactive intestinal polypeptide/pituitary adenylate cyclase activating polypeptide and glucagon-like peptide 1 and evidence against the existence of mammalian homologues. J Biol Chem 273:9778-9784, 1998
21. Venanzi ES, Benoist C, Mathis D: Good riddance: thymocyte clonal deletion prevents autoimmunity. Curr Opin Immunol 16:197-202, 2004
22. Juhl CB, Hollingdal M, Sturis J, Jakobsen G, Agerso H, Veldhuis J, Porksen N, Schmitz O: Bedtime administration of NN2211, a long-acting GLP-1 derivative, substantially reduces fasting and postprandial glycemia in type 2 diabetes. Diabetes 51:424-429, 2002
23. Kim JG, Baggio LL, Bridon DP, Castaigne JP, Robitaille MF, Jette L, Benquet C, Drucker DJ: Development and characterization of a glucagon-like peptide 1-albumin conjugate: the ability to activate the glucagon-like peptide 1 receptor in vivo. Diabetes 52:751-759, 2003
24. Baggio LL, Huang Q, Brown TJ, Drucker DJ: A recombinant human glucagon-like peptide (GLP)-1-albumin protein (albugon) mimics peptidergic activation of GLP-1 receptor-dependent pathways coupled with satiety, gastrointestinal motility, and glucose homeostasis. Diabetes 53:2492-2500, 2004
25. Hui H, Yu R, Bousquet C, Perfetti R: Transfection of pancreatic-derived beta-cells with a minigene encoding for human glucagon-like peptide-1 regulates glucose-dependent insulin synthesis and secretion. Endocrinology 143:3529-3539, 2002
26. Islam MS, Rahman SA, Mirzaei Z, Islam KB: Engineered beta-cells secreting dipeptidyl peptidase IV-resistant glucagon-like peptide-1 show enhanced glucose-responsiveness. Life Sci 76:1239-1248, 2005
27. Oh S, Lee M, Ko KS, Choi S, Kim SW: GLP-1 gene delivery for the treatment of type 2 diabetes. Mol Ther 7:478-483, 2003